Overview

Malaria in Early Life Study

Status:
Completed
Trial end date:
2017-05-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effectiveness of different malaria control strategies in the first year of life. The effectiveness of delivering an intermittent screening and treatment programme with dihydroartemisinin-piperaquine (DHP), linked to local immunization programmes, will be compared to the current practice of passive case detection of malaria. This study has two objectives: 1. To assess the effectiveness of intermittent screening and treatment with dihydroartemisinin-piperaquine (DHP) administered at 2, 3, 4 and 9 months of age compared with the current practice of passive detection and treatment for malaria in an area with high drug resistance levels to both P. falciparum and P. vivax. 2. To evaluate the safety, efficacy and population pharmacokinetics of DHP in children under 1 year of age.
Phase:
N/A
Details
Lead Sponsor:
Gadjah Mada University
Collaborators:
Eijkman Institute for Molecular Biology
Eijkman Institute, Jakarta, Indonesia
Menzies School of Health Research
Timika Research Facility, Indonesia
Treatments:
Artemisinins
Artenimol
Dihydroartemisinin
Piperaquine